{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:38:04Z","timestamp":1787017084250,"version":"build-2736575974"},"reference-count":18,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T00:00:00Z","timestamp":1738195200000},"content-version":"unspecified","delay-in-days":29,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000836","name":"University of Liverpool","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100000836","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Resp Res"],"accepted":{"date-parts":[[2024,12,5]]},"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cystic fibrosis (CF) is associated with a historically high treatment burden which causes anxiety and exhaustion for parents of children with CF, especially in the early years of a child\u2019s life. Recently, a new medication, elexacaftor\/tezacaftor\/ivacaftor (ETI), has become available to some people with CF, which has had a significant impact on the quality of life of older children and adults. This medication will soon be available for children ages 2\u20135 in the UK. This study investigated parents\u2019 perspectives before their children could start ETI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>10 parents of young children with CF participated in semistructured online focus groups. The data were analysed using thematic analysis to identify key themes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Three reviewers identified four main themes: (1) The \u2018roller coaster\u2019 of parental emotions: Shock, hope, uncertainty and anticipation, (2) The dark side of the unknown, side effects and burden of decision making, (3) The value of simple pleasures in a life with CF; treatment burden, normality, future, family life and (4) Reforming clinical care in the new era of CF care; support, communication and the future.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Parents experience a range of emotions from the day of diagnosis. While ETI brings hope and positivity, parents are concerned about the medication\u2019s safety. Parents have clear hopes and wishes for their child\u2019s future and reflect on the need for clinicians to consider reforming clinical care in the new era of CF for those eligible for new therapies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjresp-2024-002522","type":"journal-article","created":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T09:55:25Z","timestamp":1738230925000},"page":"e002522","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Qualitative study exploring the views and perceptions of parents\/carers of young children with CF regarding the introduction of CFTR modulator therapy (The REVEAL study; PaRents pErspectiVEs of KAftrio in chiLdren aged 2\u20135)"],"prefix":"10.1136","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-7767-6076","authenticated-orcid":false,"given":"Sioned Haf","family":"Davies","sequence":"first","affiliation":[{"name":"University of Liverpool School of Health Sciences, Liverpool, UK"},{"name":"Alder Hey Children\u2019s NHS Foundation Trust, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faye","family":"Wade","sequence":"additional","affiliation":[{"name":"Alder Hey Children\u2019s NHS Foundation Trust, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Fogg","sequence":"additional","affiliation":[{"name":"Alder Hey Children\u2019s NHS Foundation Trust, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Walsh","sequence":"additional","affiliation":[{"name":"Alder Hey Children\u2019s NHS Foundation Trust, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin W","family":"Southern","sequence":"additional","affiliation":[{"name":"Alder Hey Children\u2019s NHS Foundation Trust, Liverpool, UK"},{"name":"Department of Women's and Children's Health, Institute of Life Course and Medical Sciences, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,1,30]]},"reference":[{"key":"2026010701501211000_12.1.e002522.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2023.01.005"},{"key":"2026010701501211000_12.1.e002522.2","doi-asserted-by":"crossref","DOI":"10.1136\/bmjresp-2022-001420","article-title":"Exploring the impact of elexacaftor-tezacaftor-ivacaftor treatment on opinions regarding airway clearance techniques and nebulisers: TEMPO a qualitative study in children with cystic fibrosis, their families and healthcare professionals","volume":"9","author":"Almulhem","year":"2022","journal-title":"BMJ Open Respir Res"},{"key":"2026010701501211000_12.1.e002522.3","doi-asserted-by":"crossref","DOI":"10.1177\/17534666221086416","article-title":"Caregiver burden in cystic fibrosis: a systematic literature review","volume":"16","author":"Daly","year":"2022","journal-title":"Ther Adv Respir Dis"},{"key":"2026010701501211000_12.1.e002522.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychores.2007.08.017"},{"key":"2026010701501211000_12.1.e002522.5","doi-asserted-by":"crossref","DOI":"10.3390\/ijns8040053","article-title":"Psychosocial Issues Related to Newborn Screening: A Systematic Review and Synthesis","volume":"8","author":"Tluczek","year":"2022","journal-title":"Int J Neonatal Screen"},{"key":"2026010701501211000_12.1.e002522.6","first-page":"30","article-title":"Psychosocial needs and interventions for young children with cystic fibrosis and their families","volume":"46","author":"Li","year":"2023","journal-title":"Paediatr Respir Rev"},{"key":"2026010701501211000_12.1.e002522.7","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-023-36244-2","article-title":"Future therapies for cystic fibrosis","volume":"14","author":"Allen","year":"2023","journal-title":"Nat Commun"},{"key":"2026010701501211000_12.1.e002522.8","unstructured":"European Medicines Agency . Kaftrio. 2020. Available: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/kaftrio"},{"key":"2026010701501211000_12.1.e002522.9","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1002\/ppul.26953","article-title":"Exploring perceptions of and decision-making about CFTR modulators","volume":"59","author":"Landess","year":"2024","journal-title":"Pediatr Pulmonol"},{"key":"2026010701501211000_12.1.e002522.10","doi-asserted-by":"publisher","DOI":"10.1191\/1478088706qp063oa"},{"key":"2026010701501211000_12.1.e002522.11","doi-asserted-by":"publisher","DOI":"10.1080\/0142159X.2022.2057287"},{"key":"2026010701501211000_12.1.e002522.12","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1177\/1744987107081254","article-title":"Memoing in qualitative research","volume":"13","author":"Birks","year":"2008","journal-title":"J Res Nurs"},{"key":"2026010701501211000_12.1.e002522.13","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1177\/17423953221099042","article-title":"The psychological implications and health risks of cystic fibrosis pre- and post- CFTR modulator therapy","volume":"19","author":"Keyte","year":"2023","journal-title":"Chronic Illn"},{"key":"2026010701501211000_12.1.e002522.14","doi-asserted-by":"crossref","DOI":"10.1186\/s12890-022-01825-2","article-title":"Lived experiences of individuals with cystic fibrosis on CFTR-modulators","volume":"22","author":"Page","year":"2022","journal-title":"BMC Pulm Med"},{"key":"2026010701501211000_12.1.e002522.15","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph19106114","article-title":"Evaluating the Effect of Kaftrio on Perspectives of Health and Wellbeing in Individuals with Cystic Fibrosis","volume":"19","author":"Aspinall","year":"2022","journal-title":"Int J Environ Res Public Health"},{"key":"2026010701501211000_12.1.e002522.16","doi-asserted-by":"publisher","DOI":"10.1136\/adc.2008.150789"},{"key":"2026010701501211000_12.1.e002522.17","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1016\/j.pec.2020.02.025","article-title":"Misunderstandings, misperceptions, and missed opportunities: Perspectives on adherence barriers from people with CF, caregivers, and CF team members","volume":"103","author":"Eaton","year":"2020","journal-title":"Patient Educ Couns"},{"key":"2026010701501211000_12.1.e002522.18","doi-asserted-by":"publisher","DOI":"10.1016\/S1569-1993(02)00075-9"}],"container-title":["BMJ Open Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjresp-2024-002522","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T09:50:26Z","timestamp":1767779426000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopenrespres.bmj.com\/lookup\/doi\/10.1136\/bmjresp-2024-002522"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1,30]]},"published-print":{"date-parts":[[2025,1]]}},"alternative-id":["10.1136\/bmjresp-2024-002522"],"URL":"https:\/\/doi.org\/10.1136\/bmjresp-2024-002522","relation":{},"ISSN":["2052-4439"],"issn-type":[{"value":"2052-4439","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]}}}